Acetyldigitoxin
Acylanid (acetyldigitoxin) is a small molecule pharmaceutical. Acetyldigitoxin was first approved as Acylanid on 1982-01-01. The pharmaceutical is active against sodium/potassium-transporting ATPase subunit alpha-1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetyldigitoxin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACYLANID | Novartis | N-009436 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
432 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Oxidative stress | D018384 | EFO_1001905 | 3 | 5 | 3 | 1 | 3 | 14 | |
| Chronic renal insufficiency | D051436 | N18 | 1 | 3 | 6 | 1 | 3 | 13 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | 3 | 3 | 3 | 11 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 7 | — | 2 | — | 11 |
| Cocaine-related disorders | D019970 | F14 | 5 | 4 | — | 1 | — | 10 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 2 | 2 | 3 | 3 | 10 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 4 | — | 3 | 1 | 9 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 2 | 4 | 3 | 9 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 3 | — | 2 | 1 | 8 |
| Alcoholic hepatitis | D006519 | EFO_1001345 | K70.1 | — | — | 3 | 1 | 1 | 5 |
Show 52 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 7 | 6 | 3 | — | 1 | 15 | |
| Chemical and drug induced liver injury | D056486 | 1 | 3 | 2 | — | 1 | 5 | ||
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | 1 | 3 | 1 | — | — | 4 | |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 4 | 2 | — | — | 4 | |
| Pulmonary fibrosis | D011658 | J84.10 | 1 | 1 | 2 | — | — | 3 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 2 | — | 1 | 3 |
| Retinitis pigmentosa | D012174 | HP_0000580 | H35.52 | 1 | 1 | 1 | — | — | 3 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 2 | 1 | 1 | — | — | 3 |
| Coronary artery disease | D003324 | I25.1 | — | — | 3 | — | — | 3 | |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 2 | 2 | — | 1 | 3 |
Show 38 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 3 | — | — | 1 | 6 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | 2 | — | — | 2 | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 2 | — | — | 1 | 4 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 4 | — | — | — | 4 |
| Dry eye syndromes | D015352 | H04.12 | 3 | 1 | — | — | — | 4 | |
| Aging | D000375 | GO_0007568 | R41.81 | 3 | 1 | — | — | — | 3 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 2 | 2 | — | — | — | 3 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 3 | — | — | — | 3 |
| Self-injurious behavior | D016728 | HP_0100716 | R45.88 | 1 | 2 | — | — | — | 3 |
| Liver failure | D017093 | HP_0001399 | K72.9 | — | 2 | — | — | 1 | 3 |
Show 89 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | 1 | 6 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | 1 | — | — | — | 1 | 2 |
| Ovarian epithelial carcinoma | D000077216 | 1 | — | — | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Vagus nerve stimulation | D055536 | 1 | — | — | — | — | 1 | ||
| Feeding and eating disorders | D001068 | F50 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 2 | 2 | |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | — | — | — | 1 | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | — | — | 1 | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 1 | 1 |
| Exercise-induced asthma | D001250 | J45.990 | — | — | — | — | 1 | 1 | |
| Humans | D006801 | STY/T016 | — | — | — | — | 1 | 1 |
Show 32 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ACETYLDIGITOXIN |
| INN | acetyldigitoxin |
| Description | 3'''-O-acetyldigitoxin is a cardenolide glycoside compound consisting of digitoxin having an acetyl substituent at the 3-position on the D-ribo-hexopyranosyl residue at the non-reducing end. It has a role as an anti-arrhythmia drug, a cardiotonic drug and an enzyme inhibitor. It is functionally related to a digitoxin. |
| Classification | Small molecule |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 1111-39-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545057 |
| ChEBI ID | 53773 |
| PubChem CID | 5284512 |
| DrugBank | DB00511 |
| UNII ID | 0ZV4Q4L2FU (ChemIDplus, GSRS) |
Target
Agency Approved
ATP1A1
ATP1A1
Organism
Homo sapiens
Gene name
ATP1A1
Gene synonyms
NCBI Gene ID
Protein name
sodium/potassium-transporting ATPase subunit alpha-1
Protein synonyms
ATPase, Na+/K+ transporting, alpha 1 polypeptide, Na(+)/K(+) ATPase alpha-1 subunit, Na+/K+ ATPase 1, Na, K-ATPase, alpha-A catalytic polypeptide, Na,K-ATPase alpha-1 subunit, Na,K-ATPase catalytic subunit alpha-A protein, Sodium pump subunit alpha-1, sodium-potassium ATPase catalytic subunit alpha-1, sodium-potassium-ATPase, alpha 1 polypeptide
Uniprot ID
Mouse ortholog
Atp1a1 (11928)
sodium/potassium-transporting ATPase subunit alpha-1 (Q91Z09)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 42 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,344 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more